[1] 中华医学会,中华医学会杂志社,中华医学会消化病学分会,等.酒精性肝病基层诊疗指南(实践版·2019)[J].中华全科医师杂志,2020,19(11):997-1001.
[2] 王洪岩,李鑫,徐有青.酒精性肝病发病机制研究进展[J].实用肝脏病杂志,2014,17(1):5-8.
[3] 王晓霞,邹正升,李保森,等.2002至2011年中国“北方”地区住院肝硬化患者病因构成及变化趋势分析[J].实用肝脏病杂志,2014,17(2):154-158.
[4] REHM J,SAMOKHVALOV A V,SHIELD K D.Global Burden of Alcoholic Liver Diseases[J].Journal of Hepatology,2013,59(1):160-168.
[5] 张雪,汤善宏,张勇.MELD评分在终末期肝病中的临床应用进展[J].西南军医,2021,23(3):234-237.
[6] PUGH R N H,MURRAY-LYON I M,DAWSON J L,et al.Transection of the Oesophagus for Bleeding Oesophageal Varices[J].British Journal of Surgery,1973,60(8):646-649.
[7] MALINCHOC M,KAMATH P S,GORDON F D,et al.A Model to Predict Poor Survival in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunts[J].Hepatology,2000,31(4):864-871.
[8] KAMATH P S, WIESNER R H, MALINCHOC M, et al.A Model to Predict Survival in Patients with End-Stage Liver Disease[J].Hepatology,2001,33(2):464-470.
[9] 李晶莹,陆伦根.终末期肝病模型对肝硬化患者预后评估价值的研究进展[J].临床肝胆病杂志,2011,27(7):768-771; 782.
[10] KAMATH P S,KIM W R.The Model for End-Stage Liver Disease (MELD)[J].Hepatology,2007,45(3):797-805.
[11] WIESNER R,EDWARDS E,FREEMAN R,et al.Model for End-Stage Liver Disease (MELD) and Allocation of Donor Livers[J].Gastroenterology,2003,124(1):91-96.
[12] 张志华,巩晓欢,韩永荣,等.Child-Pugh、MELD、MELD-Na和iMELD评分对乙型肝炎肝硬化患者3个月和1年生存率的评估价值[J].胃肠病学,2018,23(1):24-28.
[13] 章迪,许欢,唐少华.MELD分级与Child分级对LDLT患者的短期预后分析比较[J].湖南师范大学学报(医学版),2017,14(3):20-24.
[14] SACLEUX S C,SAMUEL D.A Critical Review of MELD as a Reliable Tool for Transplant Prioritization[J].Seminars in Liver Disease,2019,39(4):403-413.
[15] 陈翀.MELD评分与血清总胆固醇水平评估失代偿期乙肝肝硬化患者预后的价值[D].合肥:安徽医科大学,2011.
[16] BERNARDI M,GITTO S,BISELLI M.The MELD Score in Patients Awaiting Liver Transplant:Strengths and Weaknesses[J].Journal of Hepatology,2011,54(6):1297-1306.
[17] HUO T I,LIN H C,WU J C,et al.Limitation of the Model for End-Stage Liver Disease for Outcome Prediction in Patients with Cirrhosis-Related Complications[J].Clinical Transplantation,2006,20(2):188-194.
[18] GAO B,BATALLER R.Alcoholic Liver Disease:Pathogenesis and New Therapeutic Targets[J].Gastroenterology,2011,141(5):1572-1585.
[19] MATHURIN P,BEUZIN F,LOUVET A,et al.Fibrosis Progression Occurs in a Subgroup of Heavy Drinkers with Typical Histological Features[J].Alimentary Pharmacology and Therapeutics,2007,25(9):1047-1054.
[20] MATHURIN P,O'GRADY J,CARITHERS R L,et al.Corticosteroids Improve Short-Term Survival in Patients with Severe Alcoholic Hepatitis:Meta-Analysis of Individual Patient Data[J].Gut,2011,60(2):255-260.
[21] SRIKUREJA W,KYULO N L,RUNYON B A,et al.MELD Score is a Better Prognostic Model Than Child-Turcotte-Pugh Score or Discriminant Function Score in Patients with Alcoholic Hepatitis[J].Journal of Hepatology,2005,42(5):700-706.
[22] DUNN W,JAMIL L H,BROWN L S,et al.MELD Accurately Predicts Mortality in Patients with Alcoholic Hepatitis[J].Hepatology,2005,41(2):353-358.
[23] PALANIYAPPAN N,SUBRAMANIAN V,RAMAPPA V,et al.The Utility of Scoring Systems in Predicting Early and Late Mortality in Alcoholic Hepatitis:Whose Score is It Anyway?[J].International Journal of Hepatology,2012,2012:1-5.
[24] KADIAN M,KAKKAR R,DHAR M,et al.Model for End-Stage Liver Disease Score Versus Maddrey Discriminant Function Score in Assessing Short-Term Outcome in Alcoholic Hepatitis[J].Journal of Gastroenterology and Hepatology,2014,29(3):581-588.
[25] PAPASTERGIOU V,TSOCHATZIS E A,PIERI G,et al.Nine Scoring Models for Short-Term Mortality in Alcoholic Hepatitis:Cross-Validation in a Biopsy-Proven Cohort[J].Alimentary Pharmacology & Therapeutics,2014,39(7):721-732.
[26] LOUVET A,LABREUCHE J,ARTRU F,et al.Combining Data from Liver Disease Scoring Systems Better Predicts Outcomes of Patients with Alcoholic Hepatitis[J].Gastroenterology,2015,149(2):398-406.
[27] 李晨,朱冰,吕飒,等.327例重症酒精性肝炎患者临床特点及其近期预后[J].中国肝脏病杂志(电子版),2016,8(4):32-38.
[28] FORREST E H,ATKINSON S R,RICHARDSON P,et al.Application of Prognostic Scores in the STOPAH Trial:Discriminant Function is no Longer the Optimal Scoring System in Alcoholic Hepatitis[J].Journal of Hepatology,2018,68(3):511-518.
[29] 朱萍,赵和平,韩涛,等.不同肝病基础的重症酒精性肝炎患者短期预后评估及其影响因素[J].临床肝胆病杂志,2021,37(2):370-374.
[30] 郝书理,李保森,孙颖,等.130例酒精性肝衰竭患者临床特点与预后分析[J].实用肝脏病杂志,2014,17(2):136-140.
[31] 郭秀丽,徐有青.CTP、MELD、MELD-Na、iMELD评分系统对酒精性肝硬化患者短期预后价值的比较[J].临床内科杂志,2011,28(11):756-758.
[32] 谢艳迪,封波,高燕,等.酒精性肝硬化患者死亡风险的预测因素[J].临床肝胆病杂志,2013,29(11):852-857.
[33] 韩雪松.MELD及其联合血清钠对失代偿期酒精性肝硬化患者预后的评价[D].沈阳:中国医科大学,2011.
[34] KRIGE J,SPENCE R T,JONAS E,et al.A New Recalibrated Four-Category Child-Pugh Score Performs Better Than the Original Child-Pugh and MELD Scores in Predicting In-Hospital Mortality in Decompensated Alcoholic Cirrhotic Patients with Acute Variceal Bleeding:A Real-World Cohort Analysis[J].World Journal of Surgery,2020,44(1):241-246.
[35] 康宁,齐丽翠,袁岳,等.PTAR联合Child-Pugh及MELD评分对肝硬化患者发生慢加急性肝衰竭预测价值研究[J].胃肠病学和肝病学杂志,2020,29(10):1171-1178.
[36] 席蓉蓉,韩涛,吕佳昱,等.比较不同评分模型对酒精相关慢加急性肝衰竭患者短期预后的评估[J].世界华人消化杂志,2018,26(6):365-372.
|